Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Anhui, China.
Department of Plastic Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Anhui, China.
Theranostics. 2020 Apr 6;10(12):5412-5434. doi: 10.7150/thno.45214. eCollection 2020.
: Rheumatoid arthritis (RA) is a prototype of inflammatory arthritis in which synovial fibroblasts (SFs) play key roles in cartilage and bone destruction through tumor-like proliferation, migration, invasion and inflammation. This study aimed to research forkhead box protein C1 (FoxC1) and microRNA (miR)-141-3p, which modulate pathological changes in the synovial membrane, to find possible strategies for treating RA. : FoxC1, β-catenin and miR-141-3p gene expression in synovial tissues and SFs was quantified by real-time PCR; FoxC1 and β-catenin protein levels were evaluated by immunohistochemistry, immunofluorescence, and Western blotting. We transiently transfected human SFs with FoxC1 and β-catenin overexpression and silencing vectors and assessed proliferation, migration, invasion and inflammation by cell function and enzyme-linked immunosorbent assays. We also assessed downstream signaling activation using immunofluorescence, real-time PCR and Western blotting. Double luciferase, coimmunoprecipitation and chromatin immunoprecipitation assays were used to verify miR-141-3p, FoxC1 and β-catenin gene and protein combinations. Finally, the therapeutic effects of FoxC1 silencing and miR-141-3p overexpression were evaluated in type II collagen-induced arthritis (CIA) rats. : We found that FoxC1 expression was significantly upregulated in synovium and SFs in both RA patients and rats with collagen-induced arthritis (CIA). FoxC1 overexpression increased β-catenin messenger RNA (mRNA) and protein levels and upregulated cyclin D1, c-Myc, fibronectin and matrix metalloproteinase 3 (MMP3) mRNA and protein expression in RA SFs (RASFs). In contrast, FoxC1 knockdown reduced β-catenin mRNA and protein levels as well as cyclin D1, c-Myc, and fibronectin mRNA and protein levels in RASFs. Furthermore, altering FoxC1 expression did not significantly change GSK3β and pGSK3β levels. FoxC1 overexpression promoted proliferation, migration, invasion and proinflammatory cytokine (interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α)) production and reduced anti-inflammatory cytokine (IL-10) levels in RASFs. FoxC1 bound to the β-catenin promoter, and β-catenin mediated the FoxC1-induced pathological changes. We also observed downregulated microRNA (miR)-141-3p expression in SFs from both RA patients and CIA rats and further found that miR-141-3p bound to the FoxC1 3'UTR and suppressed FoxC1 expression. Intra-ankle miR-141-3p agomir or FoxC1-specific siRNA injection hindered CIA development in rats. : FoxC1 and miR-141-3p participate in RA pathogenesis by mediating inflammation and SF proliferation, migration, and invasion and thus could be novel targets for RA therapy as a nonimmunosuppressive approach.
类风湿关节炎(RA)是炎症性关节炎的典型代表,滑膜成纤维细胞(SFs)通过肿瘤样增殖、迁移、侵袭和炎症在软骨和骨破坏中起关键作用。本研究旨在研究叉头框蛋白 C1(FoxC1)和微小 RNA(miR)-141-3p,它们调节滑膜膜的病理变化,寻找治疗 RA 的可能策略。
通过实时 PCR 定量检测滑膜组织和 SFs 中的 FoxC1、β-连环蛋白和 miR-141-3p 基因表达;通过免疫组织化学、免疫荧光和 Western blot 评估 FoxC1 和 β-连环蛋白蛋白水平。我们通过细胞功能和酶联免疫吸附试验瞬时转染人 SFs 过表达和沉默载体,并评估增殖、迁移、侵袭和炎症。我们还通过免疫荧光、实时 PCR 和 Western blot 评估下游信号转导激活。双荧光素酶、共免疫沉淀和染色质免疫沉淀测定用于验证 miR-141-3p、FoxC1 和 β-连环蛋白基因和蛋白组合。最后,在 II 型胶原诱导性关节炎(CIA)大鼠中评估 FoxC1 沉默和 miR-141-3p 过表达的治疗效果。
我们发现,RA 患者和胶原诱导性关节炎(CIA)大鼠的滑膜和 SF 中 FoxC1 表达明显上调。FoxC1 过表达增加了 RA SFs(RASFs)中的β-连环蛋白 mRNA 和蛋白水平,并上调了细胞周期蛋白 D1、c-Myc、纤连蛋白和基质金属蛋白酶 3(MMP3)mRNA 和蛋白表达。相反,FoxC1 敲低降低了 RASFs 中的β-连环蛋白 mRNA 和蛋白水平以及细胞周期蛋白 D1、c-Myc 和纤连蛋白 mRNA 和蛋白水平。此外,改变 FoxC1 表达并没有显著改变 GSK3β 和 pGSK3β 水平。FoxC1 过表达促进增殖、迁移、侵袭和促炎细胞因子(白细胞介素(IL)-1β、IL-6 和肿瘤坏死因子-α(TNF-α))的产生,并降低抗炎细胞因子(IL-10)水平在 RASFs 中。FoxC1 与 β-连环蛋白启动子结合,β-连环蛋白介导 FoxC1 诱导的病理变化。我们还观察到 RA 患者和 CIA 大鼠的 SFs 中 miR-141-3p 表达下调,进一步发现 miR-141-3p 与 FoxC1 3'UTR 结合并抑制 FoxC1 表达。踝关节内 miR-141-3p 激动剂或 FoxC1 特异性 siRNA 注射可抑制 CIA 大鼠的发病。
FoxC1 和 miR-141-3p 通过调节炎症和 SF 增殖、迁移和侵袭参与 RA 的发病机制,因此可作为一种非免疫抑制方法成为 RA 治疗的新靶点。